Drug Discovery Seminars – Efficient small molecule drug discovery using high fidelity DNA-encoded library technologies

DNA-encoded libraries have in recent years become increasingly popular. Pivotal, for success, is the quality of the library as well as the reliability of the screening technology.

The YoctoReactor (yR) is a technology for preparing DNA-encoded libraries with maximal fidelity. Three dimensional DNA structures are formed. Each 3D DNA structure serves as a single-molecule chemical reactor, which comprises a volume in the order of a yoctoliter (10-24 L). The DNA is used both for enabling the synthesis of the library compounds, purification handle during the library synthesis, and as barcodes for the compounds.

The Binder Trap Enrichment (BTE) is a homogeneous (immobilization-free) screening technology. BTE employs a unique principle of trapping small molecule binders together with the protein target in miniscule droplets and enables identification of potent inhibitors with low false-positive rates.

These second-generation technologies are shown to enable the discovery of low nanomolar cellular active inhibitors of both classical small molecule targets such as kinases, and more challenging small molecule targets such as protein-protein interaction targets and epigenetic targets.



Dr Nils Hansen, CEO
Vipergen ApS


A short speaker biography:

Dr. Nils Hansen is the CEO and founder of Vipergen ApS. He is the principal inventor of the enabling YoctoReactor® and Binder Trap Enrichment® drug discovery technology platforms. He previously worked for Praecis Pharmaceuticals Inc., (Waltham, MA, USA) and Symphogen A/S, (Copenhagen, Denmark). Dr. Hansen earned his Ph.D. in immunology from the University of Copenhagen, Denmark in 2000 and his M.Sc. in Chemistry and Biotechnology from the University of Aarhus, Denmark in 1996.